The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When
FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and …

EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC)
patients is inevitable. Identification of resistance mechanisms and corresponding targeting …

Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a
pathway characterized by recurring alterations in cancer. Its dysregulations enhance cancer …

Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule
targeted cancer drugs with promising therapeutic possibilities for a wide variety of …

Gastric cancer (GC) is the third leading cause among all cancer deaths globally. Although
the treatment outcome of GC has improved, the survival of patients with GC at stages III and …

Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in
various human cancer diseases. Recently, the first compounds received FDA approval in …

Despite recent advances in the systemic treatment of metastatic gastric cancer (GC),
prognostic outcomes remain poor. Considerable research effort has been invested in …

Fibroblast growth factor receptors (FGFRs), a family of transmembrane receptors with
intracellular tyrosine kinase domains, and fibroblast growth factors (FGFs) form the …

For advanced cancers of the digestive system, personalized, precise treatment can be life
saving. With the development of next-generation sequencing technology, detection of fusion …